Islet transplantation can restore endogenous beta-cell function to subjects with type 1 diabetes. Sixty-five patients received an islet transplant in Edmonton as of 1 November 2004. Their mean age was 42.9 +/- 1.2 years, their mean duration of diabetes was 27.1 +/- 1.3 years, and 57% were women. The main indication was problematic hypoglycemia. Forty-four patients completed the islet transplant as defined by insulin independence, and three further patients received >16,000 islet equivalents (IE)/kg but remained on insulin and are deemed complete. Those who became insulin independent received a total of 799,912 +/- 30,220 IE (11,910 +/- 469 IE/kg). Five subjects became insulin independent after one transplant. Fifty-two patients had two transplants, and 11 subjects had three transplants. In the completed patients, 5-year follow-up reveals that the majority ( approximately 80%) have C-peptide present post-islet transplant, but only a minority ( approximately 10%) maintain insulin independence. The median duration of insulin independence was 15 months (interquartile range 6.2-25.5). The HbA(1c) (A1C) level was well controlled in those off insulin (6.4% [6.1-6.7]) and in those back on insulin but C-peptide positive (6.7% [5.9-7.5])...Continue Reading
Associated Clinical Trials
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation site-determined
Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion
Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis
Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus
Successful [correction of Succesful] transplantation of human islets in recipients bearing a kidney graft
Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence
Histopathological study of intrahepatic islets transplanted in the nonhuman primate model using edmonton protocol immunosuppression
Human islet transplantation from pancreases with prolonged cold ischemia using additional preservation by the two-layer (UW solution/perfluorochemical) cold-storage method
Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation
Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival?
Pancreatectomy with islet autotransplantation for the treatment of severe chronic pancreatitis: the first 40 patients at the leicester general hospital
Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience
Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity?
Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody
Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center
Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation
Beta-cell replacement therapy (pancreas and islet transplantation) for treatment of diabetes mellitus: an integrated approach
Influence of islet transportation on pancreatic islet allotransplantation in type 1 diabetic patients within the Swiss-French GRAGIL network
Portal vein thrombosis complicating islet transplantation in a recipient with the Factor V Leiden mutation
Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection
Magnetic resonance-defined perinephric edema after clinical islet transplantation: a benign finding associated with mild renal impairment
Tissue factor and CCL2/monocyte chemoattractant protein-1 released by human islets affect islet engraftment in type 1 diabetic recipients
The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells
Prospective prediction of spontaneous but not recurrent autoimmune diabetes in the non-obese diabetic mouse
Improved vascular engraftment and function of autotransplanted pancreatic islets as a result of partial pancreatectomy in the mouse and rat
Vascular endothelial growth factor as a survival factor for human islets: effect of immunosuppressive drugs
Simultaneous islet-kidney vs pancreas-kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up.
Amyloid formation results in recurrence of hyperglycaemia following transplantation of human IAPP transgenic mouse islets.
The synthetic liver X receptor agonist GW3965 reduces tissue factor production and inflammatory responses in human islets in vitro.
Neural crest stem cells increase beta cell proliferation and improve islet function in co-transplanted murine pancreatic islets.
Human islet cell implants in a nude rat model of diabetes survive better in omentum than in liver with a positive influence of beta cell number and purity.
In vivo non-viral gene delivery of human vascular endothelial growth factor improves revascularisation and restoration of euglycaemia after human islet transplantation into mouse liver.
Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2).
Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient
Implanted islets in the anterior chamber of the eye are prone to autoimmune attack in a mouse model of diabetes
Insulin-producing cells derived from stem/progenitor cells: therapeutic implications for diabetes mellitus.
Monitoring the survival of islet transplants by MRI using a novel technique for their automated detection and quantification.
On the way to a diabetes cure? Improvement of glycemic control through islet transplantation with the use of a standardized common protocol: international trial of the Edmonton protocol for islet transplantation
Improving islet transplantation by gene delivery of hepatocyte growth factor (HGF) and its downstream target, protein kinase B (PKB)/Akt
Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.
Autoimmune Diabetes & Tolerance
Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.
American Diabetes Association Journals
Discover the latest diabetes research published by the journals from the American Diabetes Association.
Antihypertensive Agents: Mechanisms of Action
Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.